Treatment of a murine leukemia with chlorambucil bound monoclonal antibodies

Mice bearing a murine T cell leukemia (P388) were treated with a battery of monoclonal antibodies specific for normal T cell differentiation antigens. Therapy was evaluated during the early course of disease by DNA cell cycle analysis and recovery of leukemia cells from tumor bearing mice. This form of therapy was shown to be ineffective. However, treatment with chlorambucil bound monoclonal antibodies was shown to be effective in reducing the number of leukemia cells undergoing DNA synthesis and mitosis, in addition to diminishing the tumor burden as compared to control mice. The potential benefits of this form of therapy are discussed.